Rainbow Seed Fund Invests in AgPlus Diagnostics
AgPlus’ handheld electrochemical reader to deliver the next generation of rapid diagnostics Rainbow Seed Fund,…read more
AgPlus Diagnostics has developed a diagnostic platform technology based on research conducted at the UK’s National Physical Laboratory (NPL).
AgPlus’ platform technology combines novel electrochemistry and metallic nanoparticles signalling with diagnostic immunoassays to provide high sensitivity and fully quantitative analyte detection. The AgPlus ADVANTAGE handheld portable reader and single-use test cartridge are expected to be used across multiple applications and sectors, critically where fast cost-effective diagnostic results will enable users to make decisions, with confidence, in minutes, not hours or days.
Associated Fund Rainbow Seed Fund
Sector Medical / Biotechnology
AstraZeneca and AgPlus Diagnostics present clinical data from a novel, 10 minute, electrochemical point...read more